OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with...
Hence then, the article about oncoinvent reports updated 18 month data from phase 1 ovarian cancer trial with radspherin no new recurrences demonstrate continued promise of preventing disease progression was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression )
Also on site :
- Barcelona vs Real Madrid: Kick-Off Time, TV Channel, Live Stream and Expected Lineups for El Clásico
- Christopher Abbott Gushes Over Welcoming First Child with Partner Aubrey Plaza: ‘It’s Like the Best Movie Ever’
- The U.S. military and NASA have power problems. Nuclear microreactors might solve both